Market Research Report
Alzheimer's Disease - Pipeline Review, H1 2019
|Published by||Global Markets Direct||Product code||232776|
|Published||Content info||1429 Pages
Delivery time: 1-2 business days
|Alzheimer's Disease - Pipeline Review, H1 2019|
|Published: April 29, 2019||Content info: 1429 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H1 2019, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.
Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 25, 56, 60, 5, 295, 109 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 97 and 43 molecules, respectively.
Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.